Literature DB >> 27399172

Double Trouble: Kinase domain duplication as a new path to drug resistance.

Hsin-Yi Chen, Donita C Brady, Jessie Villanueva1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27399172      PMCID： PMC5223244          DOI： 10.1111/pcmr.12508

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  5 in total

1.  Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

Authors:  Samuel J Klempner; Rodolfo Bordoni; Kyle Gowen; Henry Kaplan; Philip J Stephens; Sai-Hong Ignatius Ou; Siraj M Ali
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

2.  BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.

Authors:  Fausto J Rodriguez; Azra H Ligon; Iren Horkayne-Szakaly; Elisabeth J Rushing; Keith L Ligon; Natalie Vena; Denise I Garcia; J Douglas Cameron; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2012-09       Impact factor: 3.685

3.  Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Authors:  Lawrence N Kwong; Genevieve M Boland; Dennie T Frederick; Timothy L Helms; Ahmad T Akid; John P Miller; Shan Jiang; Zachary A Cooper; Xingzhi Song; Sahil Seth; Jennifer Kamara; Alexei Protopopov; Gordon B Mills; Keith T Flaherty; Jennifer A Wargo; Lynda Chin
Journal:  J Clin Invest       Date:  2015-02-23       Impact factor: 14.808

4.  EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Authors:  Jean-Nicolas Gallant; Jonathan H Sheehan; Timothy M Shaver; Mark Bailey; Doron Lipson; Raghu Chandramohan; Monica Red Brewer; Sally J York; Mark G Kris; Jennifer A Pietenpol; Marc Ladanyi; Vincent A Miller; Siraj M Ali; Jens Meiler; Christine M Lovly
Journal:  Cancer Discov       Date:  2015-08-18       Impact factor: 39.397

5.  Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.

Authors:  Clemens Krepler; Min Xiao; Katrin Sproesser; Patricia A Brafford; Batool Shannan; Marilda Beqiri; Qin Liu; Wei Xu; Bradley Garman; Katherine L Nathanson; Xiaowei Xu; Giorgos C Karakousis; Gordon B Mills; Yiling Lu; Tamer A Ahmed; Poulikos I Poulikakos; Giordano Caponigro; Markus Boehm; Malte Peters; Lynn M Schuchter; Ashani T Weeraratna; Meenhard Herlyn
Journal:  Clin Cancer Res       Date:  2015-12-16       Impact factor: 12.531
  5 in total
  1 in total

Review 1.  Mechanisms of receptor tyrosine kinase activation in cancer.

Authors:  Zhenfang Du; Christine M Lovly
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.